| Drug General Information |
| Drug ID |
D0GB2L
|
| Former ID |
DIB016022
|
| Drug Name |
SNN-0031
|
| Synonyms |
Platelet derived growth factor (parkinson's disease), NeuroNova; PDGF-BB (parkinson's disease), NeuroNova
|
| Indication |
Brain injury [ICD10:S09.90]
|
Phase 1/2 |
[1]
|
|---|
| Company |
NeuroNova AB
|
| Target and Pathway |
| Target(s) |
Beta platelet-derived growth factor receptor |
Target Info |
Modulator |
|
|---|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Calcium signaling pathway
|
|
Cytokine-cytokine receptor interaction
|
|
PI3K-Akt signaling pathway
|
|
Focal adhesion
|
|
Gap junction
|
|
Regulation of actin cytoskeleton
|
|
HTLV-I infection
|
|
Pathways in cancer
|
|
MicroRNAs in cancer
|
|
Glioma
|
|
Prostate cancer
|
|
Melanoma
|
|
Central carbon metabolism in cancer
|
|
Choline metabolism in cancer
|
|
PANTHER Pathway
|
Angiogenesis
|
|
PDGF signaling pathway
|
|
Pathway Interaction Database
|
Signaling events mediated by PTP1B
|
|
Beta3 integrin cell surface interactions
|
|
S1P3 pathway
|
|
Nectin adhesion pathway
|
|
Signaling events mediated by TCPTP
|
|
SHP2 signaling
|
|
S1P1 pathway
|
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
|
|
PDGFR-beta signaling pathway
|
|
Validated targets of C-MYC transcriptional repression
|
|
PDGF receptor signaling network
|
|
Reactome
|
PIP3 activates AKT signaling
|
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
|
RAF/MAP kinase cascade
|
|
WikiPathways
|
Regulation of Actin Cytoskeleton
|
|
MAPK Signaling Pathway
|
|
Osteoblast Signaling
|
|
Focal Adhesion
|
|
PIP3 activates AKT signaling
|
|
PDGF Pathway
|
|
Signaling Pathways in Glioblastoma
|
|
Signaling by PDGF
|
| References |
| REF 1 | ClinicalTrials.gov (NCT02408562) Study on Tolerability of Repeat i.c.v. Administration of sNN0031 Infusion Solution in Patients With PD. U.S. National Institutes of Health. |
|---|
